Clavyst Bio
Accelerating Life Sciences Innovations with Ties to Singapore
Key Highlights
- Empowering Singapore’s Rise as a Global Life Sciences Powerhouse: Singapore is emerging as a global biotech hub, attracting major players and investments. Under the guidance of Khoo Shih, a seasoned executive and investor, ClavystBio aims to fund and build biotech companies with ties to Singapore, and realize the country’s potential to bring new medicines to patients in need across the globe.
- Pioneering Biotech Investments in the US and Asia: With 20+ years of experience investing in life science companies globally, Khoo Shih was previously responsible for growing the life science portfolio at Temasek – Singapore’s state-owned investment company with a net portfolio value of $290 billion. After spinning out the work into ClavystBio, Khoo Shih led investments into multiple companies with operations in Singapore and the U.S., including Engine Biosciences, Allay Therapeutics, Paratus Sciences, Sunbird Bio and more.
- What’s Next for Biotech Investing? As leader in life science venture building, ClavystBio can weigh in on the future of biotech investing, including promising trends, the potential of cross-border collaborations and the benefits of tapping into emerging markets.